

# ForPatients

by Roche

Non Small Cell Lung Carcinoma

## A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT05872763 ML44633

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are newly diagnosed with unresectable stage IIIB/IIIC/IV Non-Small-Cell Lung Cancer (NSCLC) in the selected sites. This study aims to describe the clinical practice and long-term survival benefits of patients newly diagnosed with unresectable stage IIIB/IIIC/IV NSCLC. The study also seeks to explore the condition of biomarker tests utilization, and to assess potential economic impact on patients in the real world. The safety related events will also be summarized in this study.

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT05872763 ML44633**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
AllAges

**Healthy Volunteers**  
No

---